Abstract
Tamoxifen is used in the treatment of hormone responsive breast cancer because of its antiestrogenic effect. However, it also has an estrogenic effect on the uterus, thereby increasing the risk of endometrial hyperplasia, endometrial polyp and endometrial neoplasms such as endometrial adenocarcinoma and malignant mixed Mullerian tumour (MMMT). This case describes the possible pathogenesis and risk of developing MMMT due to long-term tamoxifen intake in hormone responsive breast cancer.
2015 BMJ Publishing Group Ltd.
MeSH terms
-
Antineoplastic Agents, Hormonal / adverse effects*
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Female
-
Humans
-
Middle Aged
-
Mixed Tumor, Mullerian / chemically induced*
-
Selective Estrogen Receptor Modulators / adverse effects*
-
Selective Estrogen Receptor Modulators / therapeutic use
-
Tamoxifen / adverse effects*
-
Tamoxifen / therapeutic use
-
Uterine Neoplasms / chemically induced*
-
Uterus / pathology*
Substances
-
Antineoplastic Agents, Hormonal
-
Selective Estrogen Receptor Modulators
-
Tamoxifen